VTR to Apply to be listed on GEM Again

Guangdong VTR Bio-Tech Co., Ltd. (VTR) is ready to apply for getting listed on  the Growth Enterprise Market (GEM) again for the company's future development in mid-2012, according to CCM International’s February Issue of Industrial Biotechnology China News. Before, VTR had applied for getting listed on GEM in April 2011, but unfortunately, it failed.

Aiming to be listed on GEM this time, according to the VTR's new company environmental protection report in November 2011, it is claimed that the company has cut its fund raising programs from 5 to 3. One is the program of heat resistant phytase's and neutral phtase's technological improvement and their industrialization, and the other is the program of the marketing network service's construction. Therefore, the sum of the raised fund decreases from USD29.4 million to USD22.5 million. (TABLE) "Compared with the first failure, it is more optimistic about the second time that VTR has the potential to be listed on GEM in mid-2012." says Mr. Luo, Manager of VTR.

 

In fact, in April 2011, China Securities Regulatory Commission (CSRC) commented on VTR's first listing failure mainly for the following three reasons. Firstly, the continued growth in accounts receivable balances, which accounts highly for the company's total assets, may have the potential risk of capital return. Besides, the decreasing sales volume of the company's main products, feed compound enzymes, and the uncertainty of the increasing sales volume of feed phytase would affect the company's business picture. The last main question is the uncertainty of enzyme market digestion of the fund raising program of enzymes product expansion existed. 

 

Mr. Luo explains that the company's listing project of this time has been done a little fixing in connection with the CSRC's comment. As it mentioned above, the company has cut two fund raising programs to raise the opportunity to be listed on GEM. Also, although the common feed phytase market has been in over supply currently in China, Mr. Luo is confident on its company's product sales, especially as its heat resistant phytase industrialization has become true. The company has made some heat resistant comparisons on different brands heat resistant phytase and it is concluded that the heat resistance of VTR's product is better than the other's, said by Mr. Luo. Moreover, the company will launch its neutral phytase product in two years, which will make the company consolidate its domestic feed phytase market share.  

However, even CSRC complains about VTR's fund raising program of enzyme capacity expansion, the company insists on the reservation of the enzyme capacity expansion attributed to the phytase's bright future. The program is to construct the second phase of enzymes production line with capacity of 12,000t/a, located in Inner Mongolia Autonomous Region. Actually, the company that mainly produces phytase has the enzymes production line with capacity of 8,000t/a. Mr. Luo is optimistic about the phytase's bright future mainly thanks to the rapid growth of livestock and poultry industry. It is predicted that the meat consumption will be more substantial with the improvement of farmers' income in some regions of China. The document named The Twelfth Five-Year Plan of National Livestock and Poultry Genetic Resources Conservation and Utilization claims that the proportion of large-scale breeding of livestock and poultry in the whole nation will increase by 10%-15% by 2015. Phytase, which efficiently increase the animal dietary phosphorus utilization so as to reduce the feeding cost, will become the active stock in the near future.

VTR is a high-tech enterprise, which employs modern bioengineering technology and advanced techniques of botanic extraction and is committed to research, development and manufacture of feed additive and animal health products. Founded in 1991, the company is the first feed enzyme enterprise integrating a complete network of R&D, manufacture and sales. The company has achieved great progress and glories these years. In 2009, it drafted the determine method of feed phytase activity and determine method of feed xylanase activity. In 2010, "Yiduozyme" was authorized as the Famous Trademark in Guangdong Province.

Source: Industrial Biotechnology China News 1202

http://www.cnchemicals.com/Newsletter/NewsletterDetail_21.html

Main content of  Industrial Biotechnology China News 1202:

Shenzhen Dingsanhua to invest in bioenergy

PGCG to invest in castor oil-based diesel in China

Guofeng Bioenergy to build a biodiesel plant in Anhui Province

Wuhan Kaidi biomass energy business relying on Chinese government's support

VTR to apply to be listed on GEM again

Trade analysis of butanol in China

L-phe domestic capacity expansion to launch in 2012

Shandong Polymer to construct a subsidiary company 

Kingfa to launch a new PBS resin production line in October 2012

Arkema to purchase Suzhou HiPro and Hebei CASDA in early 2012

Trade analysis of PLA in China

Inner Mongolia Melic Sea to launch PPC production line in early 2013

……

Industrial Biotechnology China News, a monthly publication issued by CCM International on 8th of every month, focuses on biofuels, bio-products, bio-based chemicals, bio-materials and industrial biotechnology applications, offers latest investment hotspots, new technology & product, company & market dynamics, and government regulations, aiming to facilitate your insight into China's industrial biotechnology.

About CCM

CCM is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer.

For more information, please visit http://www.cnchemicals.com.

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China

Tel: 86-20-37616606

Email: econtact@cnchemicals.com

Source: http://www.cnchemicals.com/PressRoom/PressRoomDetail_w_968.html

Grandhope Successfully Launched IPO Initial Public Offerings

Guangzhou China, August 9, 2011 – CCM has released the latest issue of Industrial Biotechnology China News on July 7, 2011, with the top news that Grandhope Biotech Co., Ltd. (Grandhope) launched Initial Public Offerings (IPO) in Shenzhen Growth Enterprise Market (GEM)

Grandhope's successful listing, which will break the foreign enterprises' monopoly in the medical device industry, depends on its technology and insight of the medical device industry market. The improved technology makes its products full of high stability, low immunogenicity and tissue regeneration inducement, which had their own advantages in the industry competition.

The company plans to invest about USD38 million in the construction of national regenerative medical implants engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business. Grandhope is optimistic about its products' future prospects in domestic medical device market, especially in meningeal medical market.

What’s more, this issue focuses on the chemical fiber in China. Many China's enterprises, such as Baosteel and Shandong Jingdian, strive to develop biofuel industry in order to occupy good position in new energy area. Aiming at the biology industry, this issue also focuses on not only the biobased chemical of the SA program and L-tryptophan expansion in China, but also bioproduct such as Angel Yeast's project and domestic hemicellulase investment.

More highlights are covered in the latest issue of Industrial Biotechnology China News:

-Shandong Jingdian plans to industrially produce glycerin-based PG in 2012.-Baosteel is making efforts to promote  industrialization of carbon monoxide-based fuel ethanol.-Celanese may begin industrial ethanol production in China in 2013.                                                                                                -China's export volume of butanol increased, while its import volume decreased.                                                                                                                        -Angel Yeast is going to accelerate its expansion of yeast capacity.                                                                                                               -Hemicellulase has been attracting more and more investment in China.                                                                                                   -CAS plans to accelerate the commercial production of sialic acid (SA) by fermentation method in the future.-Some domestic L-tryptophan producers are actively promoting expansion.-Changjiang Chemical Fiber successfully completed the trial production of PLA fiber.                                                                        -RSPC invested in a new plan by its raised fund for a PTT production line with capacity of  90,000t/a.

-Three polyvinyl alcohol (PVA) production lines of Wanwei Updated High-tech Material Industry Co., Ltd.  (Wanwei Updated High-tech) will be launched in 2011-2012.                                                                                                                                                                       -China's PLA import volume significantly rose in H1 2011 year on year.                                                                                       -Grandhope launched Initial Public Offerings (IPO) in Shenzhen Growth Enterprise Market (GEM).

About CCM

CCM is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer.
Please visit http://www.cnchemicals.com for more information or contact econtact@cnchemicals.com

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China

Grandhope Launches IPO in Shenzhen Growth Enterprise Market

August 9, 2011, CCM - Grandhope Biotech Co., Ltd. (Grandhope) launched Initial Public Offerings (IPO) in Shenzhen Growth Enterprise Market (GEM) on July 7, 2011. It plans to invest about USD38 million in the construction of national regenerative medical implants engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business, according to CCM’s August Issue of Industrial Biotechnology China News.
 
Grandhope has become the sixth listed biomedical enterprises in Guangzhou, China. Mr. Zhu, chairman of the board in Grandhope, claimed that the listing of Grandhope would help the company establish more comprehensive management mechanism. It was a good chance to achieve the effective combination between the management of production and the use of resource and capital.

The raised fund for Grandhope's IPO will be mainly applied to these investments: construction of regenerative medical implants national engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business. Mr. Zhu especially explained the strategy of the first three projects: the construction of the laboratory, which costs Grandhope USD5.9 million, would lead the company to strengthen the core competitiveness in the high-tech field. In order to get more profit and market share, Grandhope invested USD3.1 million in  high-tech industrialization of sterile biological membrane, which would promote the adjustment of the product structure. The market expansion valued at USD7.7 million would improve the company's influence in the market.  

Grandhope's successful listing depends on its technology and insight of the medical device industry market.

Grandhope mainly relies on its independent R&D to get into the medical device industry. Grandhope is a high-tech enterprise engaged in regenerative medical materials and medical implants development, production and sales. Because of Grandhope's independent R&D, it has developed a new type medical material made by cow's or pig's membranes, which belongs to the extracellular matrix material. Based on the technology of extracellular material, Grandhope's products develop epoxy tissue fixation technology, full antigen-technology and mechanics induced modification technology and organizational techniques to resolve the weakness of the traditional extracellular matrix material. Its product has the capability of high stability, low immunogenicity and tissue regeneration inducement which had their own advantages in the industry competition. Grandhope applied these to launch its products such as biotype hard brain membrane, general thoracic surgical repair membrane and sterile bio-protection membrane.

Extracellular matrix material, which will replace the conventional biomedical materials such as synthetical biomaterials and alloy materials, can adhere to the injury compatibly. By its function, it can replace the disease tissue's function during the cell regeneration. Furthermore, the cell regeneration can be induced by this material compared with the conventional biomedical materials, which just play a short term alternative role to the injury. 

Grandhope is optimistic about its products' future prospects in domestic medical device market, especially in meningeal medical market. Grandhope gained great profit mainly from its brain membrane from 2006 to 2010. The products' actual quantity had been accumulated to100,000 till 2010 without medical negligence. Its biotype brain membrane, higher cost performance than the products from foreign enterprises, has occupied 43% of China's biotype brain membrane's market share in 2010 instead of 32% in 2008. Compared with Grandhope's products, the market share of foreign companies, such as Germany's B. Braun Medical, Johnson & Johnson, etc., declined gradually from 45% in 2008 to 25% in 2010. Mr. Zhang, deputy general manager of Grandhope, predicted that the biotype brain membrane market would maintain 20% annual growth because of craniotomy increasing, which would increase the market demand. Meanwhile, the sales of general thoracic surgical repair membrane and sterile bio-protection membrane rise gradually.

Furthermore, Granhope will focus on R&D medical cosmetic surgery market in future although it has some difficulties in collaborative project with Renhe Group, this project will not be arranged in next three months.

Grandhope's insight into the global medical device industry leads the enterprise to focus on the extracellular matrix material's R&D in recent years. Owing to rapid expansion with the growth rate of 6% - 12% per year from 2006 to 2008, the global medical device industry is growing into the pillar industry of the global economy. In 2009, the production value of global medical device industry was over USD370 billion. More importantly, the output value of China's medical device industry is growing over 20% per year in a fast speed in 2001-2011. The profit of China's medical device industry is over USD38 billion. Surgical implant is one of the most important product categories in medical device industry. It is the most effective mean especially in cardiovascular disease and bone disease. The output value of surgical implants has reached USD6.2 billion in 2009 compared with that of USD3.1 billion in 2006. China's surgical implant's market will become the second largest market after the market in the US in the next 10 years, as China Association for Medical Devices Industry estimated.

Source: Industrial Biotechnology China News 1108

http://www.cnchemicals.com/Newsletter/NewsletterDetail.aspx?id=21

Main content of  Industrial Biotechnology China News 1108:

Shandong Jingdian to produce glycerin-based PG
Baosteel to promote industrialization of carbon monoxide-based fuel ethanol
Celanese to seize China's ethanol market
Trade analysis of China's butanol
Angel Yeast to accelerate its expansion of yeast capacity
Domestic hemicellulase investment increases greatly
CAS plans to accelerate its commercial production of SA
Rapid L-tryptophan expansion in China 
Changjiang Chemical Fiber makes a breakthrough on industrialization of PLA fiber
RSPC to invest in PTT fiber
Wanwei Updated High-tech's PVA expansion
Trade analysis of China's PLA 
Grandhope launches IPO in Shenzhen Growth Enterprise Market

Industrial Biotechnology China News, a monthly publication issued by CCM International on 8th of every month, focuses on biofuels, bio-products, bio-based chemicals, bio-materials and industrial biotechnology applications, offers latest investment hotspots, new technology & product, company & market dynamics, and government regulations, aiming to facilitate your insight into China's industrial biotechnology.

Please visit http://www.cnchemicals.com for more information or contact us at econtact@cnchemicals.com.